NeuroPace’s stock has delivered impressive returns, with a year-to-date price increase of over 46%, according to InvestingPro data. Despite this strong performance, the company is currently trading at ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and NeuroPace AI platform will be ...

MOUNTAIN VIEW, Calif., December 02, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced ...

NeuroPace (NPCE) remains unprofitable, but earnings are forecast to grow 64.52% per year. The company is expected to reach profitability within the next three years. Revenue is projected to climb at a ...

Investing.com - NeuroPace Inc (NASDAQ:NPCE) maintained its Overweight rating and $16.00 price target from Cantor Fitzgerald following strong third-quarter 2025 results. The stock, currently trading at ...

MOUNTAIN VIEW, Calif. (AP) — MOUNTAIN VIEW, Calif. (AP) — NeuroPace Inc. (NPCE) on Tuesday reported a loss of $3.5 million in its third quarter. The Mountain View, California-based company said it had ...

NeuroPace has hired the former chief financial officer of Staar Surgical, Patrick Williams, to replace its current financial chief. The medical-device company said Tuesday that Rebecca Kuhn has ...

NeuroPace, Inc. (NASDAQ:NPCE) is among the best NASDAQ stocks under $50 to buy. Cantor Fitzgerald reiterated its Overweight rating on NeuroPace, Inc. (NASDAQ:NPCE), with a price target of $16.00, ...

What is it like to go between practicing medicine and working at a startup? Dr. Martha Morrell, NeuroPace’s CMO, discusses the transition and dives into three-year effectiveness data from the ...

MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that ...